drugset
drugset / Trial / NCT05701436

Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial

NCT05701436 ↗

Phase 3 Unknown 144 enrolled Zhujiang Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This Randomized Controlled Trial was to clarity the clinical feasibility of 3D-HDRA results in guiding the drug use of interventional chemotherapy after primary liver cancer surgery.

Timeline

Start
2022-09-01
Primary completion
2026-01-01
Completion
2026-03-01

Drugs

EvaluationDrugModalityDoseRoute
Background Cisplatin Other / unclassified 50 mg/m2 Other
Background Doxorubicin Other / unclassified 20 mg/m2 Other
Background Leucovorin Small molecule 400 mg/m2 Other
Background Lobaplatin Small molecule 50 mg/m2 Other
Background Oxaliplatin Small molecule 130 mg/m2 Other
Background Raltitrexed Small molecule 3 mg/m2 Other
Background fluorouracil Small molecule 2800 mg/m2 Other

Indications

liver cancer